Caitlin Flanagan

March 30, 2021

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, and Sara A. Hurvitz, M.D., discuss treatment approaches and modifications during the COVID-19 pandemic.

March 30, 2021

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, discusses the learning curve of taking an oral medication, tucatinib, in combination with chemotherapy, and Sara A. Hurvitz, M.D., reviews methods for medication adherence.

March 30, 2021

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, discusses how her quality of life has been since she began taking tucatinib with chemotherapy.

March 30, 2021

Sara A. Hurvitz, M.D., reviews the advances in HER2+ metastatic breast cancer that have been made over the past decade.

March 30, 2021

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, shares her goals of treatment after progression of disease.

March 30, 2021

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, shares the hope she had after progression because of the ongoing research for HER2+ breast cancer, and Sara A. Hurvitz, M.D., reviews the drug regimens available in this realm.

March 16, 2021

Sara A. Hurvitz, M.D., reviews the history of HER2+ breast cancer and the progressive research that has been done in this disease.

March 16, 2021

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, describes her experience learning about the surplus of treatment options and how she overcame her initial apprehension.

March 16, 2021

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, shares her initial impression of when she was diagnosed.

March 16, 2021

Sara A. Hurvitz, M.D., describes the subtypes, staging and grading of breast cancer.